Under the terms of the five-year agreement, Akorn will be responsible for the manufacturing and supply of the ophthalmic drug product that will be manufactured at the company’s Somerset, New Jersey facility. Akorn is the ANDA holder and also expects to launch this drug product under the Akorn label in mid-2008.
Arthur Przybyl, president and CEO of Akorn, said: “We continue to seek contract pharmaceutical manufacturing opportunities in ophthalmics, liquid injectables and lyophilized products in order to expand these businesses.”